Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

January 21, 2026
We’re delighted to share that Vasudha Tandon, PhD Principal Scientist at Pharmidex , will be attending the BBMS Gala Dinner 2026 on Thursday 22 January 2026 at the Old Hall, Queens’ College, Cambridge. This special evening, part of Building Bridges in Medical Sciences, brings together leaders from academia, industry, and healthcare to strengthen collaboration across the life sciences. Vasudha is looking forward to meeting fellow attendees and exploring new opportunities to build meaningful scientific partnerships.
January 19, 2026
Pharmidex is proud to offer comprehensive in vitro and preclinical solutions tailored to autoimmune disease research, helping accelerate the development of novel treatments. Our expertise spans multiple autoimmune indications including multiple sclerosis, psoriasis, atopic dermatitis, alopecia, colitis, immune response and vitiligo, combining rigorous proof-of-concept studies with integrated pharmacokinetic, pharmacodynamic, biomarkers analysis, histopathological evaluation of relevant organs and tissues, toxicological and bioanalytical endpoints to support fast-track research. With deep scientific knowledge and flexible study designs, we partner with researchers to deliver translationally relevant data that informs confident decision-making throughout the drug discovery and development pathway. If your team is advancing immune-modulating therapies, we’d be delighted to discuss how Pharmidex can help support your research. 🌐 www.pharmidex.com
More Posts